Abstract
Although acromegaly remains a disease primarily addressed by pituitary microsurgery, most patients require secondary treatment for persistent growth hormone (GH) hypersecretion and elevated serum insulin-like growth factor-1 (IGF-1) concentrations following adenomectomy. Persistently abnormal serum GH and IGF-1 can be reduced to normal concentrations in better than half of post-surgery acromegalics using the pharmacologic treatments available at present, the dopamine agonists (DA) and somatostatin (SST) analogs. The long-acting SST analogs octreotide LAR and lanreotide SR have become the mainstay of medical treatment for acromegaly, having largely supplanted DA agents since the introduction of bromocriptine for the suppression of GH secretion in the 1970s. The DA cabergoline may be effective in up to half of patients, however, in particular those patients whose tumors cosecrete prolactin. On the horizon is the GH-receptor antagonist pegvisomant, which is expected to enable the reduction of serum IGF-1 to the normal range in the vast majority of postoperative acromegaly patients, representing a revolutionary development in the medical treatment of this disease. We here review the choices available to the endocrinologist in the pharmacologic treatment of acromegaly, focusing upon the SST analogs.
Similar content being viewed by others
References
Marie P. and de Souza-Leite, J. D. (1886). Rev. Med. Liege 6, 297–333.
Alexander, L., Appleton, D., Hall, R., et al. (1980). Clin. Endocrinol. (Oxf.) 12, 71–79.
Bates, A. S., Van’t Hoff, W., Jones, J. M., and Clayton, R. N. (1993). Q. J. Med. 86, 293–299.
Herman, V., Fagin, J., Gonsky, R., Kovacs, K., and Melmed, S. (1990). J. Clin. Endocrinol. Metab. 71, 1427–1433.
Landis, C. A., Harsh, G., Lyons, J., Davis, R., McCormick, F., and Bourne, H. R. (1990). J. Clin. Endocrinol. Metab. 71, 1416–1420.
Freda, P. U. (1998). J. Clin. Endocrinol. Metab. 83, 3031–3033.
Freda, P. U., Wardlaw, S. L., and Post, K. D. (1998). J. Neurosurg. 89, 353–358.
Swearingen, B., Barker, F. G. II, Katznelson, L., et al. (1998). J. Clin. Endocrinol. Metab. 83, 3419–3426.
Giustina, A., Barkan, A., Casaneuva, F. F., et al. (2000). J. Clin. Endocrinol. Metab. 85, 526–529.
Trainer, P. (2002). J. Clin. Endocrinol. Metab. 87, 3534–3536.
Chiodini, P. G., Cozzi, R., Dallabonanza, D., et al. (1987). J. Clin. Endocrinol. Metab. 64, 447–453.
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., and Ibbertson, H. K. (1994). Clin. Endocrinol. (Oxf.) 41, 95–102.
Bates, A. S., Van’t Hott, W., Jones, J. M., and Clayton, R. N. (1995). Metab. Clin. Exp. 44, 1–5.
Abosch, A., Tyrrell, J. B., Lamborn, K. R., Hannegan, L. T., Applebury, C. B., and Wilson, C. B. (1998). J. Clin. Endocrinol. Metab. 83, 3411–3418.
Freda, P. U., Post, K. D., Powell, J. S., and Wardlaw, S. L. (1998). J. Clin. Endocrinol. Metab. 83, 3808–3816.
Costa, A. C. F., Rossi, A., Martinelli, C. E. Jr., Machado, H. R., and Moreira, A. C. (2002). J. Clin. Endocrinol. Metab. 87, 3142–3147.
Melmed, S., Ho, K., Klibanski, A., Reichlin, S., and Thorner, M. (1995). J. Clin. Endocrinol. Metab. 80, 3395–3402.
Dimaraki, E. V., Jaffe, C. A., DeMott-Friberg, R., Chandler, W. F., and Barkan, A. L. (2002). J. Clin. Endocrinol. Metab. 87, 3537–3542.
Kovacs, K. and Horvath, E. (1987). Endocrinol. Metab. Clin. North Am. 16, 529–551.
Tabarin, A., Carrie, F., Ronci, N., et al. (1996). In: Proceedings of the 4th International Pituitary Congress, San Diego (abstract H5).
Jaffe, C. A. and Barkan, A. L.. (1994). Endcrinol. Metab. Clinics North Am. 21, 713–735.
Liuzzi, A., Chiodini, P. G., Botalla, L., Cremascoli, G., Müller, E. E., and Silvestrini, F. (1974). J. Clin. Endocrinol. Metab. 38, 910–914.
Summers, V. K., Hipkin, L. J., Diver, M. J., and Davis, J. C. (1975). J. Clin. Endocrinol. Metab. 40, 904–908.
Barkan, A. L., Beitins, I. Z., and Kelch, R. P. (1988). J. Clin. Endocrinol. Metab. 67, 69–73.
Kleinberg, D. L., Boyd, A. E. III, Wardlaw, S., et al. (1983). N. Engl. J. Med. 309, 704–709.
Kendall-Taylor, P., Upstill-Goddard, G., and Cook, D. (1983). Clin. Endocrinol. 19, 711–719.
Ferrari, C., Paracchi, A., Romano, C., et al. (1988). Clin. Endocrinol. 29, 467–476.
Muratori, M., Arosio, M., Gambino, G., Romano, C., Biella, O., and Faglia, G. (1997). J. Endocrinol. Invest. 20, 537–546.
Colao, A., Ferone, D., Marzullo, P., et al. (1997). J. Clin. Endocrinol. Metab. 82, 518–523.
Jackson, S. N. J., Fowler, J., and Howlett, T. A. (1997). Clin. Endocrinol. 46, 745–749.
Abs, R., Verhelst, J., Dominique, M., et al. (1998). J. Clin. Endocrinol. Metab. 83, 374–378.
Cozzi, R., Attanasio, R., Barausse, M., et al. (1998). Eur. J. Endocrinol. 139, 516–521.
Krulich, L., Dhariwal, A. P. S., and McCann, S. M. (1968). Endocrinology 83, 783–790.
Pradayrol, L., Jornvall, H., Mutt, V., and Ribet, A. (1980). FEBS Lett. 109, 55–88.
Reichlin, S. (1983). N. Engl. J. Med. 309, 1495–1501.
Reichlin, S. (1983). N. Engl. J. Med. 309, 1556–1563.
Yamada, Y., Reisine, T., Laws, S. F., et al. (1992). Mol. Endocrinol. 6, 2136–2142.
O’Carroll, A. M., Lolait, S. J., Konig, M., and Mahan, L. C. (1992). Mol. Pharmacol. 42, 939–946.
Yamada, Y., Post, S. R., Wang, K., Tager, H. S., Bell, G. I., and Seino, S. (1992). Proc. Natl. Acad. Sci. USA 89, 251–255.
Stewart, P. M. and James, R. A. (1999). Baillière’s Clin. Endocrinol. Metab. 13, 409–418.
Panetta, R. and Patel, Y. C. (1995). Life Sci. 56, 333–342.
Jaquet, P., Saveanu, A., Gunz, G., et al. (2000). J. Clin. Endocrinol. Metab. 85, 781–792.
Reubi, J. C. and Landolt, A. M. (1989). J. Clin. Endocrinol. Metab. 68, 844–850.
Lamberts, S. W. J., van Der Lely, A.-J., de Herder, W. W., and Hofland, L. J. (1996). N. Engl. J. Med. 334, 246–254.
Bauer, W., Briner, U., Doepfner, W., et al. (1982). Life Sci. 31, 1133–1140.
Ho, K. Y., Weissberger, A. J., Marbach, P., and Lazarus, L. (1990). Ann. Intern. Med. 112, 173–181.
Lamberts, S. W., Uitterlinden, P., Verschoor, L., van Dongen, K. J., and del Pozo, E. (1985). N. Engl. J. Med. 313, 1576–1580.
Comi, R. J. and Gorden, P. (1987). J. Clin. Endocrinol. Metab. 64, 37–42.
Lamberts, S. W., Uitterlinden, P., and del Pozo, E. (1987). J. Clin. Endocrinol. Metab. 65, 703–710.
Barkan, A. L., Kelch, R. P., Hopwood, N. J., and Beitins, I. Z. (1988). J. Clin. Endocrinol. Metab. 66, 16–23.
Vance, M. L. and Harris, A. G. (1991). Arch. Int. Med. 151, 1573–1578.
Ducasse, M. C., Tauber, J. P., Tourre, A., et al. (1987). J. Clin. Endocrinol. Metab. 65, 1042–1046.
Barkan, A. L., Lloyd, R. V., Chandler, W. F., et al. (1988). J. Clin. Endocrinol. Metab. 67, 1040–1048.
Atkin, A. L., Lowry, M., Hill, C. R., and Turnbull, L. W. (2002). In: Proceedings of the Endocrine Society’s 84th Annual Meeting, San Francisco (abstract P1–222).
Lancranjan, I., Bruns, C., Grass, P., et al. (1996). Metabolism 45, 67–71.
Grass, P., Marbach, P., Bruns, C., and Lancranjan, I. (1996). Metabolism 45, 27–30.
Biermasz, N. R., van den Oever, N. C., Pereira Arias, A. M., Smit, J. W., Romijn, J. A., and Roelfsema, F. (2002). In: Proceedings of the Endocrine Society’s 84th Annual Meeting, San Francisco (abstract P1–225).
Heron, I., Thomas, F., Dero, M., et al. (1993). J. Clin. Endocrinol. Metab. 76, 721–727.
Caron, P. (2002). Annales Endocrinologie 63, 2S19–2S24.
Freda, P. U. (2002). J. Clin. Endocrinol. Metab. 87, 3013–3018.
Colao, A., Cuocolo, A., Marzullo, P., et al. (1999). J. Clin. Endocrinol. Metab. 84, 17–23.
Colao, A., Marzullo, P., Ferone, D., et al. (2000). J. Clin. Endocrinol. Metab. 85, 3132–3140.
Newman, C. B., Melmed, S., Snyder, P. J., et al. (1995). J. Clin. Endocrinol. Metab. 80, 2768–2775.
Colao, A., Ferone, D., Marzullo, P., et al. (2001). J. Clin. Endocrinol. Metab. 86, 2779–2786.
Murray, R. D., Kim, K., Ren, S. G., Weckbecker, G., Bruns, C., and Melmed, S. (2002). In: Proceedings of the Endocrine Society’s 84th Annual Meeting. San Francisco (abstract OR58-6).
Daughaday, W. H., Trivedi, B., and Andrews, B. A. (1987). J. Clin. Endocrinol. Metab. 65, 1072–1074.
Fuh, G., Mulkerrin, M. G., Bass, S., et al. (1990). J. Biol. Chem. 265, 3111–3115.
Ultsch, M., De Vos, A. M., and Kossiakoff, A. A. (1991). J. Mol. Biol. 222, 865–868.
Cunningham, B. C., Ultsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R., and Wells, J. A. (1991). Science 254, 821–825.
De Vos, A. M., Ultsch, M., and Kossiakoff, A. A. (1992). Science 255, 306–312.
Cunningham, B. C., Henner, D. J., and Wells, J. A. (1990). Science 247, 1461–1465.
Fuh, G., Cunningham, B. C., Fukunaga, R., Goeddel, D. V., and Wells, J. A. (1992). Science 256, 1677–1680.
Chen, W. Y., Chen, N. Y., Yun, J., et al. (1995). Mol. Endocrinol. 9, 292–302.
Cunningham, B. C., Lowman, H. B., Wells, J. A., Clark, R. G., Olson, K., and Fuh, G. (1998). US Patent no. 5. 849:535.
Lowman, H. B. and Wells, J. A. (1993). J. Mol. Biol. 234, 564–578.
Parkinson, C. and Trainer, P. J. (1999). Baillère’s Clin. Endocrinol. Metab. 13, 419–430.
Trainer, P. J., Drake, W. M., Katznelson, L., et al. (2000). N. Engl. J. Med. 342, 1171–1177.
van der Lely, A. J., Hutson, K. R., Trainer, P. J., et al. (2001). Lancet 358, 1754–1759.
Besser, M. and Hutson, K. In: Proceedings of the Endocrine Society’s 84th Annual Meeting, San Francisco (abstract OR 13-3).
Abe, T. and Ludecke, D. (2001). Eur. J. Endocrinol. 145, 137–145.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Racine, M.S., Barkan, A.L. Somatostatin analogs in medical treatment of acromegaly. Endocr 20, 271–278 (2003). https://doi.org/10.1385/ENDO:20:3:271
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:20:3:271